MMJ BioPharma 对 DEA 驳回其大麻种植申请以取得医学进步的动议提出质疑。 MMJ BioPharma challenges DEA's motion to dismiss its cannabis cultivation application for medicinal advancements.
领先的大麻研究机构 MMJ BioPharma Cultivation 正在挑战美国缉毒局 (DEA) 驳回其长期悬而未决的种植药用大麻申请的动议。 MMJ BioPharma Cultivation, a leading cannabis researcher, is challenging the Drug Enforcement Administration's (DEA) motion to dismiss its long-pending application for cultivating pharmaceutical marijuana. 该公司总裁杜安·博伊西（Duane Boise）强调这一批准对于药用大麻的进步至关重要。 The company's president, Duane Boise, emphasizes the critical importance of this approval for advancements in medicinal cannabis. 该批准将在向 MMJ BioPharma Labs 颁发附表 1 药物的 DEA 分析实验室注册后获得，以便进行大麻研究和开发。 The approval would come after the issuance of a DEA Analytical Lab Registration for Schedule 1 drugs to MMJ BioPharma Labs, allowing for cannabis research and development.